Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Saved in:
Bibliographic Details
Title: Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Authors: Wesolowski R; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Rugo HS; University of California, San Francisco Comprehensive Cancer Center, San Francisco, California., Specht JM; Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington., Han HS; Moffit Cancer Center, Tampa, Florida., Kabos P; University of Colorado Hospital, Aurora, Colorado., Vaishampayan U; Karmanos Cancer Institute, Detroit, Michigan., Wander SA; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Gogineni K; Emory University Hospital, Atlanta, Georgia., Spira A; Virginia Cancer Specialists Research Institute, Fairfax, Virginia., Schott AF; University of Michigan, Ann Arbor, Michigan., Abu-Khalaf M; Sidney Kimmel Comprehensive Cancer Center at Jefferson Health, Philadelphia, Pennsylvania., Mutka SC; Celcuity, Inc., Minneapolis, Minnesota., Suzuki S; Celcuity, Inc., Minneapolis, Minnesota., Sullivan B; Celcuity, Inc., Minneapolis, Minnesota., Gorbatchevsky I; Celcuity, Inc., Minneapolis, Minnesota., Layman RM; The University of Texas MD Anderson Cancer Center, Houston, Texas.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Oct 01; Vol. 31 (19), pp. 4040-4048.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-25-0992